|Manufacturer:||Roxane Laboratories, Inc.|
There are insufficient data to recommend dose adjustment of zidovudine in patients with mild to moderate impaired hepatic function or liver cirrhosis.
Since zidovudine is primarily eliminated by hepatic metabolism, a reduction in the daily dose may be necessary in these patients.Frequent monitoring for hematologic toxicities is advised (see CLINICAL PHARMACOLOGY: Pharmacokinetics and PRECAUTIONS: General).
COMBIVIRCOMBIVIR® is a registered trademark of GlaxoSmithKline.
and TRIZIVIRTRIZIVIR® is a registered trademark of GlaxoSmithKline.
are combination product tablets that contain zidovudine as one of their components.Zidovudine should not be administered concomitantly with COMBIVIR or TRIZIVIR.The incidence of adverse reactions appears to increase with disease progression; patients should be monitored carefully, especially as disease progression occurs.